Biological basis of cannabinoid medicines

Mechanistic insights into cannabinoid signaling could improve therapeutic applications.

American Association for the Advancement of Science

Abstract

Since its first mention ∼4000 BCE, Cannabis sativa has evolved through selective cultivation from being a source of durable fiber (hemp) to a plant enriched in bioactive ingredients. Currently, >100 potentially bioactive phytocannabinoids from Cannabis spp. have been cataloged, yet their precise structure-function relationships are mostly unclear (1). Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are primarily studied, particularly because high-grade Cannabis subspecies can produce over 20% yield of either compound. The variety of bioactive constituents in C. sativa, together with their defined ratios, suggests that they have potential application in many illnesses (1). Possibly due to many phytocannabinoids producing similar pharmacological effects through different mechanisms, selecting which to study for a disease remains a formidable challenge.

Read More

Get helpful, doctor-recommended medical cannabis news and tips delivered to your inbox.

* We respect your privacy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Continue Reading

Pain

Biological basis of cannabinoid medicines

Pain

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential

Pain

Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings

Continue Reading